Solara Active Pharma Sciences Limited (SOLARA) Earnings Call Transcripts

Solara Active Pharma Sciences Limited's Latest Earnings Call - Q4 FY2026

Solara Active Pharma Sciences Limited reported a strong Q4 FY '26, with the highest revenue, gross margins, and EBITDA in the past eight quarters. Revenue grew by 12% QoQ to INR 392 crores, while EBITDA surged 65% QoQ to INR 61 crores, driven by the base business. The company maintained a 26% EBITDA margin. Management did not provide specific forward guidance but emphasized a focus on sustainable growth and operational efficiency. The ongoing strategic review of the ibuprofen business remains a key area of focus.

Reported metrics

Guidance from management

Management did not provide specific forward guidance but emphasized a focus on sustainable growth and operational efficiency. The strategic review of the ibuprofen business is expected to conclude in H1 '27.

What management said

So let me go first. Firstly, if you see our revenue growth have grown 12%, we've grown from around the base of the business. So on the base business, Sajal, we have a very healthy order book, and you've seen that in our numbers as well. So I'm very encouraged looking at this order book and the utilization across our facilities that there is a strong performance, and it is not factors outside our control that are real...

No, no, no, Sajal. There's nothing one-off there. And like always, our story continues despite all the headwinds we are facing and the money that we are losing on the ibuprofen business, I think our base business is what's driving the momentum is what's keeping the tailwinds also. Again, coming back to your first answer. There's no one-off here.

What analysts pressed on

Analysts expressed concerns about the sustainability of the base business growth and the strategic options for the ibuprofen business. Questions focused on whether recent performance was driven by structural changes or temporary factors, and the potential impact of ibuprofen business decisions on customer relationships.

Main topics on the call

• Base Business Performance — The base business demonstrated strong momentum with a 12% QoQ revenue growth and a 65% QoQ EBITDA increase. Management emphasized that this growth is sustainable and not driven by one-off factors. 'Our base business is w...
• Ibuprofen Business Challenges — The ibuprofen segment continues to face headwinds, contributing negative EBITDA. Management has appointed bankers to evaluate strategic options, expecting a resolution in H1 '27. 'Ibuprofen business has been a drag for u...
• Operational Efficiency and Capacity Utilization — Solara is operating at 70% capacity utilization, with plans to optimize existing capacity through debottlenecking projects. 'We have around 30% capacity left that we can utilize,' mentioned Sandeep Rao.
• Debt Reduction — The company reduced its debt by INR 158 crores during FY '26, a 21% reduction, with plans to further reduce debt to INR 503 crores by the end of May '26.

Read the full Solara Active Pharma Sciences Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 24 Solara Active Pharma Sciences Limited earnings call transcripts on record, spanning February 6, 2020 to July 23, 2026. Based on this history, Solara Active Pharma Sciences Limited reports quarterly. The most recent call on file is dated July 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SOLARA

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

24

First call

February 6, 2020

Most recent

July 23, 2026

Reporting cadence

quarterly